ClinicalTrials.gg
RecruitingNCT07253883STARDUSTUpdated Oct 15, 2026

A Study to Understand the Accuracy of a New Breathing Device Compared to Standard Testing for Asthma and COPD

An observational study in Asthma (Diagnosis) and COPD (Chronic Obstructive Pulmonary Disease), sponsored by Liverpool Heart and Chest Hospital NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Liverpool Heart and Chest Hospital NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 15, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years to 110 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 558 studies in Asthma with a site in United Kingdom — 52 open to participants now, 71 under way, 11 of them phase 3. Asthma · United Kingdom.

Planned enrollment
22nd of 131
1,200 · median 149
Started
2026
with 16 others
Observational
131 of 558
24 open now
Primary completion
2027-05
later than 38 of 70 live
Registered
540th of 558
by date

Among the 558 studies in Asthma with a site in United Kingdom, this one is the 22nd largest by planned enrollment of the 131 observational ones that give a count, is one of 17 that started in 2026, is one of 131 observational ones, reaches primary completion later than 38 of the 70 other live ones, and was the 540th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

52 of the 558 studies in Asthma with a site in United Kingdom are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 110 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 558 studies in Asthma with a site in United Kingdom, or all of them as a file.
02

Study summary

The diagnosis of either asthma or chronic obstructive pulmonary disease (COPD) is currently based on a combination of symptoms, different lung tests and sometimes a 'trial by treatment'. Both COPD and Asthma tests currently include forced breathing using a test known as spirometry which can be difficult and uncomfortable for people to perform and needs expert interpretation. Asthma can require multiple tests in sequence which can make the process of diagnosis long and inconvenient for patients. In the UK, there have been challenges providing enough testing for COPD and asthma, in part because the tests are challenging to provide in the community to everyone who needs one.

The STARDUST study aims to test and develop new ways of diagnosing asthma and COPD that are quick, accurate and easy for patient and healthcare professionals to perform. People who have been referred for routine lung testing will breathe normally in and out into a handheld device called the N-Tidal Handset for 75 seconds. This device measures how the level of carbon dioxide (CO2) changes in the breath as people breath through it. The information gathered on the N-Tidal Handsets, called breath records or capnograms, will not be used to alter the diagnosis of any participants in the study.

After the capnograms have been collected, the research team will test 'algorithms' that have been developed using artificial intelligence, to see if they can accurately identify the correct diagnosis. Information collected in the study will also be used to make improvements in these algorithms.

If confirmed to be accurate, these algorithms could be used in clinical practice to help healthcare professionals make faster, more accessible and accurate diagnoses, especially in settings like GP clinics in the community where access to specialist tests may be limited.

Read the detailed description

COPD is one of the leading causes of disability and in the top five causes of death worldwide. Early diagnosis and treatment are essential to slow the decline of lung function and improve quality of life.

The current standard for diagnosing COPD is spirometry; an effort-dependent test that requires supervised use, by a specifically trained medical professional, in a clinic-based environment. It is estimated that up to 2/3 of cases are undiagnosed suggesting that there is a significant care gap in the ability to accurately diagnose COPD.

Asthma is a chronic respiratory disease, characterised by airway inflammation and hyper-responsiveness. In 2019 affected an estimated 262 million people. Early diagnosis and treatment are important to reduce symptoms, exacerbations and mortality and to improve overall quality of life. The confirmation of reversible airflow obstruction using pre- and post-bronchodilator (BD) spirometry is needed to confirm a diagnosis in those suspected as having asthma without evidence of inflammation in the airways or blood.

Spirometry can be challenging for patients to perform, is time consuming and can be challenging to deliver at the scale required by the population.

TidalSense have been developing respiratory diagnostic devices that could offer simpler, safe, fast, reliable and precise tests to diagnose both COPD and asthma.

It is anticipated that successfully meeting the primary objectives of this study will result in data on the diagnostic accuracy of the COPD diagnostic models and could lead to the development and improvement of all diagnostic algorithms used in the study. This may contribute to a range of future clinical benefits:

  • Accurate diagnosis of asthma and/or COPD
  • Accurate detection of severe COPD in patients who are likely or highly likely to have COPD
  • Improved ease of testing for asthma and/or COPD for patients and healthcare professionals
  • Clearer differentiation between asthma and COPD in patients with overlapping symptoms

These benefits could enable quicker testing, improve patient experience (relaxed breathing instead of forced breathing), and improve patient access to testing compared to current diagnostic pathways and reduce misdiagnosis.

03

Conditions studied

  • Asthma (Diagnosis)
  • COPD (Chronic Obstructive Pulmonary Disease)

Keywords

  • Asthma
  • COPD
  • End tidal CO2
  • Diagnostics
  • Machine learning
04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with a suspicion of asthma and/or COPD

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Referred for respiratory diagnostic testing with a clinical suspicion of asthma or
  • Participant is willing and able to provide

Exclusion criteria

Exclusion Criteria:

  • Referred for respiratory diagnostic testing for a condition other than asthma or , with no mention in the referral of a clinical suspicion of COPD or asthma
  • Participants who, in the opinion of the chief investigator, or their delegate, are unlikely to comply with the requirements of the study
  • Inability to give written
  • Participants who are acutely unwell
  • Patients unable to breathe through their mouths e.g. tracheostomy patients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Asthma

    Patients with suspected asthma

    Diagnostic Test: Partial pressure of CO2 during tidal breathing · Diagnostic Test: FENO · Diagnostic Test: Spirometry

  • COPD

    Patients with suspected COPD

    Diagnostic Test: Partial pressure of CO2 during tidal breathing · Diagnostic Test: FENO · Diagnostic Test: Spirometry

Interventions

  • Diagnostic testPartial pressure of CO2 during tidal breathing

    Partial pressure of CO2 during tidal breathing for diagnosis of asthma or COPD

  • Diagnostic testFENO

    Fractional exhaled nitric oxide

    Also known as: Fractional exhaled nitric oxide

  • Diagnostic testSpirometry

    Spirometry with or without bronchodilation (if indicated)

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of the diagnostic algorithms of N-Tidal Diagnose 1

    PPV, NPV, Sensitivity, Specificity compared to clinician diagnosis of COPD

    Time frame: At time of testing

  2. Diagnostic accuracy of prototype diagnostic algorithms

    Prototype asthma diagnostic algorithms (index test; PPV, NPV, Sensitivity, Specificity) trained using a combined capnogram dataset from this and previous studies, compared to clinician diagnosis of asthma

    Time frame: At time of testing

Secondary outcomes

  1. Diagnostic accuracy of the N-Tidal Diagnose 1 severity algorithm

    Diagnostic accuracy (PPV, NPV, Sensitivity, Specificity) of the N-Tidal Diagnose 1 severity algorithm in those with a confirmed diagnosis of COPD. Diagnostic accuracy (PPV, NPV, Sensitivity, Specificity) of the diagnostic algorithms embedded in NTidal Diagnose 1 v1.0 in relevant subgroups. Diagnostic accuracy (PPV, NPV, Sensitivity, Specificity) of the pre-production asthma diagnostic algorithms trained using a combined capnogram dataset from this and previous studies in relevant prespecified subgroups. Exploratory analysis of novel machine learning diagnostic algorithms for COPD and asthma.

    Time frame: At time of diagnosis

  2. Feasibility and acceptability outcomes

    Visual Analogue Score (VAS) following N-Tidal, spirometry and FeNO (ease of use and comfort for participants, ease of use only for administering healthcare professionals) in a subset of participants. Percentage of participants with a clinical suspicion of COPD with adequate N-Tidal Handset breath record capture, sufficient to generate a diagnostic output using N-Tidal Diagnose 1 v1.0 diagnostic algorithms. Percentage of participants with a clinical suspicion of asthma with adequate N-Tidal Handset breath record capture, sufficient to generate a diagnostic output using prototype asthma diagnostic algorithms.

    Time frame: At time of diagnosis

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data may be shared for future research under appropriate governance as per the terms of the collaboration agreement between TidalSense and the Liverpool Heart and Chest Hospital NHS Foundation Trust.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2027, 8 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 8 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Apr 2026 → Sep 2026 and primary completion Dec 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 28, 2025
StartActual
Sep 15, 2026was Apr 2026
Primary completionEst.
May 19, 2027was Dec 2026
CompletionEst.
May 19, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
Liverpool Heart and Chest Hospital NHS Foundation Trust is now Recruiting
Oct 15, 2026
Start date
Apr 1, 2026→Sep 15, 2026 (actual)
Oct 15, 2026
Primary completion
Dec 19, 2026→May 19, 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    Liverpool Heart and Chest Hospital NHS Foundation Trust is now Recruiting
    Start date Apr 1, 2026→Sep 15, 2026 (now actual)
    Primary completion Dec 19, 2026→May 19, 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07253883
Lead sponsor
Liverpool Heart and Chest Hospital NHS Foundation Trust
Collaborators
TidalSense
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Sep 15, 2026
Primary completion
May 19, 2027 (estimated)
Completion
May 19, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Hassan Burhan, MBChB FRCP
Contact
Hassan.Burhan@liverpoolft.nhs.uk
0151 254 3036
Thomas FitzMaurice, MBChB BSc PGCME MRCP(UK) PhD
Contact
0151 254 3055

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion